

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 09/756,690

Inventors: Kolterman, et al.

Filed: January 9, 2001

Title: *Use of Exendins and Agonists thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia*

Confirmation No.: 4666

TC/A.U.: 1646

Examiner: Dong JIANG

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicant submits copies of the references listed on the attached PTO Form PTO/SB/08A for consideration by the U.S. Patent and Trademark Office in the above-entitled application and to be made of record herein. In accordance with 37 C.F.R. 1.98, copies of U.S. Patents and U.S. Patent Application Publications are not provided herewith.


I certify that no item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned, after reasonable inquiry, no item contained in this Supplemental Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

The Commissioner is hereby authorized to charge Deposit Account No. 01-0535 the amount of \$180.00 as set forth in 37 C.F.R. 1.17(p). Applicant believes no additional fees are

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8a OR
FACSIMILE TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the USPTO at facsimile number (571) 273-8300, or deposited with the United States Postal Service on the date shown below with sufficient First Class postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

02 December 2005
Date of Deposit




Renee Zavala

due. If Applicant is in error, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment to Deposit Account No. 01-0535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully Submitted

AMYLIN PHARMACEUTICALS, INC.



Laurie L. Hill

Registration No. 51,804

Dated: 02 December 2005

AMYLIN PHARMACEUTICALS, INC.
9373 Towne Centre Drive
San Diego, CA 92121
Telephone: (858) 552-2200
Facsimile: (858) 552-1936

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2	Complete if Known
				Application Number 09/756,690
				Filing Date January 9, 2001
				First Named Inventor Kolterman, et al.
				Art Unit 1646
				Examiner Name JIANG, Dong
				Attorney Docket No. 249/124US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ -Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL letters), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
		Gaudio et al., "Changes in Plasma Lipids During Renin-Angiotensin System Blockade by Combination therapy (Enalapril Plus Valsartan) in Patients with Diabetes and Hypertension," <i>J. Cardiovascular Pharmacology</i> 45(4):362-366 (2005)					
		Odmark et al., "Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17 β -estradiol/norethisterone acetate on lipids and lipoproteins," <i>Maturitas</i> 48:137-46 (2004)					
		Saklamaz et al., "The beneficial effects of lipid-lowering drugs beyond lipid lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type Ia and type IIb hyperlipidemia," <i>Metabolism Clin. Exp.</i> 54:677-81 (2005)					
		Bravata et al., "Efficacy and Safety of Low-Carbohydrate Diets," <i>JAMA</i> 289(14):1837-50 (2003)f					
		Kolterman et al., "Five-Day Dosing of Synthetic Exendin-4 (AC2993) in People with Type 2 Diabetes Reduces Post-Prandial Glucose, Glucagon and Triglyceride Concentrations," <i>Diabetologia</i> 43(Suppl. 1):A189 (2000)					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number(optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 C.F.R. 1.97 and 1.98. the information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.